Tag: capital markets

Company Announcement No 55/2025  

Nasdaq powers technological development furthering trading growth

TORONTO, June 27, 2025 (GLOBE NEWSWIRE) -- The Canadian Investor Relations Institute (CIRI), Canada’s national association representing investor relations professionals, announced the 2025 CIRI Fellows.

In accordance with section 30 of the Capital Markets Act, Pandora A/S hereby announces that
BlackRock, Inc. has notified the company that it now holds 7,497,838 shares, corresponding to 9.49% of the total voting rights and share capital (previously 9.47%). Additionally, BlackRock, Inc. controls voting rights attached to financial instruments amounting to 0.51% (previously 0.50%). In total, BlackRock, Inc. control 10.0% of the company’s voting rights (previously 9.98%).

Falcon Oil & Gas Ltd.
(“Falcon”)
 Notice of Annual General and Special Shareholder Meeting

Trading to Commence Under Symbol “BTCT”

Tiburon, CA, June 26, 2025 (GLOBE NEWSWIRE) -- FIGX Capital Acquisition Corp. (the “Company”) announced today the pricing of its initial public offering of 13,100,000 units. The units are expected to be listed on The Nasdaq Global Stock Market LLC (“Nasdaq”) and begin trading tomorrow, June 27, 2025, under the ticker symbol “FIGXU.” Each unit consists of one Class A ordinary share and one-half of one redeemable warrant, each whole warrant entitling the holder thereof to purchase one Class A ordinary share at a price of $11.50 per share, subject to certain adjustments. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. An amount equal to $10.00 per unit will be deposited into a trust account upon the closing of the offering. Once the securities constituting the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on Nasdaq under the symbols “FIGX” and “FIGXW,” respectively. The offering is expected to close on June 30, 2025, subject to customary closing conditions. The Company has granted the underwriters a 45-day option to purchase up to an additional 1,965,000 units at the initial public offering price to cover over-allotments, if any.

SAN DIEGO, June 26, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (“Cidara”) (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced the closing of its underwritten public offering of 9,147,727 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,193,181 shares, at a price to the public of $44.00 per share. The gross proceeds to Cidara from the offering, before deducting underwriting discounts and commissions and offering expenses, were $402.5 million. All of the shares in the offering were sold by Cidara.